Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrends About Edge Therapeutics Stock (NASDAQ:EDGE) 30 days 90 days 365 days Advanced Chart Remove Ads Get Edge Therapeutics alerts:Sign Up Key Stats Today's Range$36.77▼$37.0850-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume107 shsAverage Volume373,201 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More… Remove Ads Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EDGE Stock News HeadlinesAlloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery PlatformFebruary 11, 2025 | businesswire.comKenox Pharmaceuticals Expands Capabilities to Strengthen Drug Development OfferingsJanuary 31, 2025 | finance.yahoo.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…March 12, 2025 | Crypto Swap Profits (Ad)Sharp Therapeutics Corp. Announces Completion of Qualifying TransactionDecember 12, 2024 | finance.yahoo.comAsimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell lineNovember 25, 2024 | msn.comMyeloid Therapeutics to Participate in Jefferies London Healthcare ConferenceNovember 14, 2024 | finance.yahoo.comNeumora Therapeutics, Inc.: Strategic Advancements and Unique Efficacy in MDD Trials Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comA Closer Look at 8 Analyst Recommendations For Amicus TherapeuticsNovember 13, 2024 | benzinga.comSee More Headlines EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Bristol-Myers Squibb (BMY), Cerecor (CERC) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/01/2018Today3/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book38.70Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$1.16 billion OptionableNot Optionable Beta3.65 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:EDGE) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
